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Background: Systemic inflammation in psoriasis causes in-
sulin resistance and cardiovascular diseases. Adipokines are 
adipose-tissue-derived factors that are involved in metabolic 
processes. It is thought that these adipokines are associated 
with the development of psoriasis. Objective: The purpose of 
this study was to determine the changes in adipokine levels, 
insulin resistance, hypertension, and dyslipidemia over a 
12-week period. Methods: The study comprised 35 psoriasis 
patients and 50 controls. Blood samples were obtained twice 
from the patients, one sample at the start and one at the end 
of a 12-week follow-up period. The following parameters 
were assessed in both groups: serum fasting glucose, fasting 
insulin, homeostasis model assessment-estimated insulin re-
sistance (HOMA-IR) index, serum lipids, adiponectin, leptin, 
resistin, chemerin, omentin, vaspin, visfatin, retinol-binding 
protein 4, and high-sensitivity C-reactive protein (hs-CRP) 
levels; blood pressure; body mass index; and the psoriasis 
area severity index (PASI) scores. Results: The patients 
showed an improvement in the PASI score and a significant 
decrease in serum hs-CRP, omentin, and chemerin values. 
Moreover, at the start of the follow-up, the psoriasis patients 
had significantly lower levels of adiponectin and visfatin and 
significantly higher levels of vaspin and resistin than those of 
the control group. Visfatin levels correlated negatively with 
low-density lipoprotein (LDL) and cholesterol, while vaspin 
and omentin levels correlated positively with diastolic blood 
pressure. Decreased adiponectin levels correlated neg-
atively with diastolic blood pressure and LDL. Conclusion: 
Plasma levels of adipokines might be useful for evaluating 
the disease activity of psoriasis and its comorbidities. (Ann 
Dermatol 28(1) 74∼79, 2016)
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INTRODUCTION
Psoriasis vulgaris is an immune-mediated chronic in-
flammatory disease of the skin1. In psoriasis, pathological 
findings are not confined only to the skin2. The pro-in-
flammatory molecules released during chronic inflam-
mation may lead to the presence of one or more disorders 
co-occurring with psoriasis, such as atherosclerosis, athe-
rogenesis, insulin resistance, hypertension, obesity, dysli-
pidemia, metabolic syndrome, and diabetes mellitus type 
22,3. As the psoriasis area severity index (PASI) score in-
creases, the risk of these accompanying disorders also in-
creases4,5. Obesity triggers inflammatory changes in the 
body. This inflammation may change the level of adipo-
kines and cytokines. Obesity-induced inflammatory changes 
may trigger some immune-mediated inflammatory diseases, 
one of which is psoriasis6. In obese patients, the levels of 
pro-inflammatory adipokines are increased and those of 
anti-inflammatory adipokines are decreased1. There have 
been various studies on the changes in adipokine levels 
and insulin resistance in psoriasis patients, but these stud-
ies have not reported consistent results. The main purpose 
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of this study was to determine the effect of decreased PASI 
scores on adipokine levels, insulin resistance, hypertension, 
and dyslipidemia. 
MATERIALS AND METHODS
This hospital-based, prospective cohort study included 35 
psoriasis patients with no evidence of psoriatic arthritis 
and 50 controls. Both groups were matched in terms of 
age, gender, and body mass index (BMI). The study was 
approved by the local ethics committee (IRB No. B.30.2. 
PAÜ.0.20.05.08-404/056). Written consent forms were 
signed by the patients volunteering to participate in the 
study. The study was carried out according to the ethical 
principles of the Declaration of Helsinki.
Study population
The study consisted of a series of psoriasis patients pre-
senting at the dermatology clinic of a medical school hos-
pital and healthy volunteers of matching age, gender, and 
BMI as the control group. The criteria for exclusion from 
the study for both groups were previous phototherapy 
and/or systemic medical therapy for psoriasis of at least 
one month duration, age under 18 years, a diffuse skin 
disease, metabolic syndrome, an accompanying systemic 
disorder, immunodeficiency, pregnancy, or breast-feeding.
Assessments 
All psoriasis patients were clinically examined, and their 
disease severity and PASI scores were determined. Venous 
blood samples were obtained twice from the patients on 
various therapies, once at the start and once at the end of 
a 12-week follow-up period, and once from the control 
group. The blood samples were examined for the following: 
fasting glucose, fasting cholesterol, triglyceride, high-density 
lipoprotein (HDL), low-density lipoprotein (LDL), adipo-
nectin, leptin, resistin, chemerin, omentin, vaspin, visfatin, 
retinol-binding protein 4 (RBP4), and high-sensitive C-re-
active protein (hs-CRP). The arterial blood pressure and 
BMI were determined for all members of both groups. 
Insulin resistance was evaluated according to the ho-
meostasis model assessment-estimated insulin resistance 
(HOMA-IR) index.
Sample collection
After an 8-hour fasting period, 15 ml of venous blood were 
drawn from the antecubital vein of all members of both 
groups. After separation of the serum, levels of fasting glu-
cose and insulin, and lipid profiles were quickly determined. 
The remaining serum sample was kept at −80oC until the 
time of use. The serum levels of adiponectin, leptin, re-
sistin, chemerin, omentin, vaspin, visfatin, RBP4, and 
hs-CRP were determined by enzyme-linked immunospecific 
assay using commercial kits. After a 12-week follow-up, a 
15 ml venous blood sample was drawn only from the pa-
tients, and the levels of fasting glucose, insulin; and adi-
pokine and lipid profiles were re-evaluated. In order to 
provide the validity of measurements, the mean values 
were calculated using computer software. 
Statistical analysis
The SPSS software ver. 17.0 (SPSS Inc., Chicago, IL, USA) 
was used for the statistical analyses of data. The Student’s 
t-test, the Mann-Whitney U test, one-sample Kolmogo-
rov-Smirnov test, and non-parametric correlation tests 
were performed. A p-value of ＜0.05 was accepted as stat-
istically significant. Numerical values were expressed as 
mean±standard deviation.
RESULTS
In 35 patients (10 women, 25 men), the mean value of the 
PASI score at the beginning of the follow-up was 5.8±1.78. 
In the 35 patients receiving systemic methotrexate ther-
apy, after the 12-week follow-up, there was a significant 
decrease in the mean PASI score (p＜0.0001). 
At the beginning of the follow-up diastolic blood pressure 
(DBP, p=0.032), cholesterol (p=0.042), and LDL (p=0.022) 
levels were markedly higher than those of controls. How-
ever, serum HDL, systolic blood pressure, triglyceride, 
and glucose levels were not significantly different. Psoriasis 
patients were insulin resistant (HOMA-IR, 2.98±3.23; nor-
mal, ＜2.5); although, the difference was not significant 
when compared to controls (Table 1). 
Statistical analyses of adipokines and hs-CRP levels be-
tween both groups showed that adiponectin (p＜0.0001) 
was significantly lower and hs-CRP (p=0.01), omentin (p
＜0.0001), resistin (p＜0.0001), chemerin (p=0.008), and 
vaspin (p＜0.0001) levels were higher, in the before treat-
ment group than in the control group. Leptin, RBP4 and 
visfatin levels were similar before treatment, after treat-
ment and in the control group. After treatment with me-
thotrexate, hs-CRP levels were similar to those of control 
group (Table 2). 
With the improvement of PASI, the patient levels of 
hs-CRP, leptin, omentin, and chemerin decreased signi-
ficantly. In contrast, serum levels of adiponectin, leptin, 
RBP4, resistin, vaspin, and visfatin, did not change sig-
nificantly before and after treatments (p＞0.05) (Fig. 1, 2).
PASI values were significantly correlated with serum 
omentin (r=0.416, p≤0.01), chemerin (r=0.614, p≤
0.01), hs-CRP (r=0.338, p≤0.01), and leptin levels 
M Coban, et al
76 Ann Dermatol
Table 1. Demographics and laboratory findings of the patients and controls
 Variable Patient (n=35) Control (n=50) p-value
Age (yr)  44.43±11.59   40.48±13.47 NS
Gender (male:female) 25:10 32:18 NS
BMI (kg/m2) 27.18±4.8  26.88±4.28 NS
DBP (mmHg)    79±12.11    74±8.3 0.032*
SBP (mmHg) 121.57±14.39 118.5±9.8 NS
Cholesterol (mg/dl) 194.43±43.65  176.44±36.22 0.042*
HDL (mg/dl)  48.48±10.81  47.92±14.1 NS
LDL (mg/dl) 119.71±34.83  102.94±30.78 0.022*
Triglyceride (mg/dl) 134.83±62.46  136.74±137.3 NS
HOMA-IR  2.98±3.23   2.32±1.43 NS
Glucose 106.11±45.37   93.64±11.77 0.06
Values are presented as mean±standard deviation and number. BMI: body mass index, NS: not significant, DBP: diastolic blood pressure,
SBP: systolic blood pressure, HDL: high density lipoprotein, LDL: low density lipoprotein, HOMA-IR: homeostasis model 
assessment-estimated insulin resistance. *p≤0.05.
Table 2. The comparisons of adipokines among before and after methotrexate treatment and control groups 
Before treatment After treatment Control P1 P2 P3
Adiponectin (ng/ml)  8.53±6.68 8.51±9.4  15.8±8.58 NS ＜0.0001* ＜0.0001*
hs-CRP (pg/ml)  2.64±1.59  1.99±0.96   1.8±1.32 0.04* 0.01* NS
Leptin (ng/ml)  2.79±1.79  2.2±1.5  2.82±1.57 NS NS NS
Omentin (ng/ml)  55.99±18.62  39.68±19.93  24.52±11.32  0.001* ＜0.0001* ＜0.0001*
RBP4 (ng/ml) 61.01±6.11 64.56±8.83 61.37±6.9 NS NS NS
Resistin (ng/ml)  4.11±1.19  4.25±1.21  3.22±0.88 NS ＜0.0001* ＜0.0001*
Chemerin (ng/ml) 125.28±39.85   3.7±0.75 100.04±36.86 ＜0.0001*  0.008* ＜0.0001*
Vaspin (pg/ml) 463.53±28.81  456.7±71.16  85.27±37.76 NS ＜0.0001* ＜0.0001*
Visfatin (ng/ml)  8.37±1.41  9.45±15.3  12.89±27.26 NS 0.054 NS
PASI  5.85±1.78  1.83±2.26 - ＜0.0001* NS NS
Values are presented as mean±standard deviation. P1: pretreatment and posttreatment comparison, P2: pretreatment and control 
comparison, P3: posttreatment and control comparison, NS: not significant, hs-CRP: high sensitive C reactive protein, RBP4: retinol
binding protein 4, PASI: psoriasis area severity index. *p≤0.05.
Fig. 1. Follow-up, adiponectin, hs-CRP, leptin, resistin, visfatin 
levels of psoriasis patients before and after systemic methotrexate 
treatment. hs-CRP: high-sensitivity C-reactive protein.
Fig. 2. Follow-up, chemerin, omentin, RBP4, vaspin levels of 
psoriasis patients before and after systemic methotrexate treat-
ment. RBP4: retinol-binding protein 4.
Adipokines in Psoriasis
Vol. 28, No. 1, 2016 77
Table 3. The correlations between adipokines and clinical parameters (r)
PASI HOMA-IR DBP BMI LDL Cholesterol
Omentin 0.416** −0.117 0.24** 0.49 0.162 0.147
Adiponectin −0.04 0.113 −0.25** −0.11 −0.207* −0.176
Leptin 0.251* 0.097 0.013 0.424** 0.009 0.026
RBP4 −0.018 0.132 0.117 −0.086 −0.024 0.012
Resistin 0.087 −0.044 0.141 0.205* 0.021 0.081
Chemerin 0.614** 0.027 −0.018 0.013 0.110 0.182*
Vaspin −0.041 0.052 0.221* −0.047 0.171 0.141
Visfatin 0.168 0.015 −0.026 −0.024 −0.215** −0.264**
hs-CRP 0.338** 0.05 0.129 0.444** 0.20* 0.207*
PASI: psoriasis area severity index, HOMA-IR: homeostasis model assessment-estimated insulin resistance, DBP: diastolic blood pressure,
BMI: body mass index, LDL: low-density lipoprotein, RBP4: retinol binding protein 4, hs-CRP: high sensitive C reactive protein. *p≤0.05,
**p≤0.01.
(r=0.251, p≤0.05). Also, the BMI was significantly corre-
lated with serum leptin (r=0.424, p≤0.01), hs-CRP 
(r=0.444, p≤0.01), and resistin (r=0.205, p≤0.05) levels. 
A significant positive correlation was observed between 
DBP and omentin (r=0.24, p≤0.01), vaspin (r=0.221, 
p≤0.05). There was a negative correlation between DBP 
and adiponectin (r=0.25, p≤0.01). A significant negative 
correlation was observed between LDL levels and adipo-
nectin (r=0.207, p≤0.05) and visfatin (r=0.215, p≤
0.01). There was a negative correlation between LDL and 
hs-CRP (r=0.20, p≤0.05) Cholesterol levels were neg-
atively correlated with serum visfatin (r=0.416, p≤0.01), 
adiponectin (r=0.614, p≤0.01). A negative correlation 
between cholesterol and serum visfatin levels was ob-
served (r=0.264, p≤0.01). The correlations between adi-
pokines and clinical parameters are presented in Table 3.
DISCUSSION
Psoriasis is a disease accompanied by systemic inflam-
mation7. Chronic inflammation predisposes to athero-
sclerosis and may subsequently lead to cardiovascular dis-
ease8,9. In the pro-inflammatory setting, insulin resistance 
may occur, which also causes atherosclerosis7,10. Insulin 
resistance is associated with pro-inflammatory cytokines 
and adipokines produced by the truncal adipose tissue. It 
has been observed that adipokine levels in psoriasis pa-
tients are similar to those observed in prediabetic in-
dividuals1.
Adipokines, some of which are anti-inflammatory and oth-
ers pro-inflammatory, have various roles in the systemic 
inflammation observed in psoriasis patients. There have 
been numerous studies on the effect of changes in the 
PASI associated with changes in adipokine levels6, but the 
findings in these studies are inconsistent.
High or low levels of adiponectin, an anti-inflammatory 
protein, have been observed in different inflammatory dis-
orders; and low levels of adiponectin have been found to 
have a different impact on the course of psoriasis11. It has 
been reported that a decrease in the PASI accompanies 
decreased levels of leptin. The values of these two param-
eters in controls have been found to be either higher or 
lower than those found in psoriasis patients12,13. 
Romani et al.14 have reported that a decrease in the PASI 
score is accompanied by an increase in omentin levels. 
Takahashi et al.15 have observed higher levels of ometin in 
controls than in patients and a negative correlation be-
tween the PASI and omentin. In our study, serum omentin 
levels correlated inversely with PASI but serum omentin 
levels in our patients were higher than in controls. This re-
sult may point to the close relationship between ometin 
and BMI. Of note, our patients had a lower BMI than 
those in the Takahashi et al.15 study. A study including pa-
tients with psoriatic arthritis16 has reported significantly 
higher levels of omentin in patients than in controls. 
The decrease in the PASI score may be accompanied by a 
decrease predominantly in RPB4 and resistin levels, but 
there are also some studies reporting an elevation in re-
sistin levels12-15. One study has determined a positive cor-
relation between RBP4 and PASI values14. However, our 
study showed that resistin levels of patients were higher 
than controls, but RBP4 levels did not differ significantly 
between patients and controls. These results may be re-
lated to the patient’s inflammatory profile, or on lifestyle 
and genetic factors. 
Gisondi et al.17 found a significant decrease in the PASI 
score and serum chemerin levels, but no correlation was 
identified between these two parameters. We observed 
higher levels of chemerin in patients than in controls and 
a strongly positive correlation between the PASI score and 
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chemerin. 
A cross-sectional study18 has reported higher levels of vas-
pin in psoriasis patients. To the best of our knowledge, 
there is no prospective study evaluating vaspin levels in 
the literature. We found that higher levels of vaspin in pa-
tients than in controls. 
It has been reported that psoriasis patients show sig-
nificantly higher levels of visfatin than controls17,19,20. In 
our study, we did not find any significant differences in 
plasma visfatin levels between patients and controls. 
Studies on hs-CRP levels have described higher levels of 
hs-CRP in psoriasis patients compared to controls, with a 
significant fall in hs-CRP as the PASI score decreases21-23. 
Kanelleas et al.22 have reported a positive correlation be-
tween hs-CRP and psoriasis, but in other studies, no corre-
lation has been found21,24. In our study, we found higher 
levels of hs-CRP in psoriasis patients compared to controls 
and a strongly positive correlation between the PASI score 
and hs-CRP levels. 
In particular, HOMA-IR values have been found to be 
higher in patients than in controls13,25,26. One study13 has 
reported that the decrease in the PASI is accompanied by 
a significant decrease in HOMA-IR values. In the present 
study, we found psoriasis patients were insulin resistant. 
Unfortunately, given our relatively small sample size, the 
difference was not significant when compared to controls. 
There are studies reporting the presence or absence of an 
association between the severity of psoriasis and blood 
pressure, with inconsistent results25,26.
The purpose of this study was to assess the effect of de-
creased PASI on hs-CRP, adipokine levels, hypertension, 
dyslipidemia, and insulin resistance in psoriasis patients. 
We found a significant decrease in PASI scores. We ob-
served that in psoriasis patients, the values of adiponectin 
and visfatin were lower, and values of omentin, resistin, 
chemerin, vaspin, and hs-CRP were higher than those in 
controls. Moreover, we found that the PASI score pos-
itively correlated with hs-CRP, omentin, and chemerin 
values. DBP, glucose, LDL, cholesterol were significantly 
higher in patients than in the controls. 
The concurrent decrease in pro-inflammatory hs-CRP and 
PASI supports the hypothesis that the inflammatory re-
sponse decreases as the PASI score improves. Moreover, 
we observed that hs-CRP showed a positive correlation 
with dyslipidemia, and obesity. 
The limitations of our study are the relatively small sam-
ples and the short duration of follow-up. The results of our 
study may be validated by further studies including more 
patients followed-up for a longer time. 
According to the results of our study, hs-CRP, omentin and 
chemerin may be used as positive markers in the clinical 
follow-up of psoriasis patients. Determination of these adi-
pokine levels may help the clinician in the clinical fol-
low-up of psoriasis patients. Our data strongly suggest that 
hs-CRP levels, in particular, will be of considerable help 
in the clinical follow-up of psoriasis patients. We also be-
lieve that the determination of HOMA-IR values, glucose, 
LDL, and cholesterol levels, as well as blood pressure con-
trol will also be of assistance in preventing the onset of 
psoriasis comorbidities.
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